Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis

Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis

Abstract Purpose To explore potential design for pharmacogenomics trials in sepsis, we investigate the interaction between pharmacogenomic biomarkers and response to drotrecogin alfa (activated) (DrotAA). This trial was designed to validate whether previously identified improved response polymorphis...

Full description

Bibliographic Details
Main Authors: Djillali Annane, Jean-Paul Mira, Lorraine B. Ware, Anthony C. Gordon, Charles J. Hinds, David C. Christiani, Jonathan Sevransky, Kathleen Barnes, Timothy G. Buchman, Patrick J. Heagerty, Robert Balshaw, Nadia Lesnikova, Karen de Nobrega, Hugh F. Wellman, Mauricio Neira, Alexandra D. J. Mancini, Keith R. Walley, James A. Russell
Format: Article
Language:English
Published: SpringerOpen 2018-01-01
Series:Annals of Intensive Care
Subjects:
Drotrecogin alfa (activated)
Activated protein C
Pharmacogenomics biomarker
Propensity score
Severe sepsis
Online Access:http://link.springer.com/article/10.1186/s13613-018-0353-2

Internet

http://link.springer.com/article/10.1186/s13613-018-0353-2

Similar Items